REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. (翰思艾泰生物医药科技(武汉)股份有限公司) (China)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Profile Updated: January 28, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

The Company was established in 2014. The Company and its subsidiaries were involved on research development of advanced biologic therapies for cancer and autoimmune diseases.

Headquarters
3/F, Building 2W, Science Park Avenue, Hong Kong Science Park, Shatin
Hong Kong; Hong Kong;

Contact Details: Purchase the Hanx Biopharmaceuticals (Wuhan) Co. Ltd. (翰思艾泰生物医药科技(武汉)股份有限公司) report to view the information.

Website: http://www.hanxbio.com

Basic Information
Financial Auditors:
Purchase the Hanx Biopharmaceuticals (Wuhan) Co. Ltd. (翰思艾泰生物医药科技(武汉)股份有限公司) report to view the information.
Incorporation Date:
February 20, 2026
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Operating Officer
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Subsidiaries
Hangzhou Hanx Biopharmaceuticals Ltd
100%
Company Performance
Financial values in the chart are available after Hanx Biopharmaceuticals (Wuhan) Co. Ltd. (翰思艾泰生物医药科技(武汉)股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Total operating revenue
-13.39%▼
Operating Profit/Loss (EBIT)
-24.83%▼
EBITDA
-20.39%▼
Net Profit/Loss for the Period
-37.3%▼
Total Assets
-14.46%▼
Total Equity
-32.22%▼
Return on Equity (ROE)
-27.33%▼
Debt/Equity
0.76%▲
Quick Ratio
-3.52%▼
Cash Ratio
-1.76%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo